Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
SEC-verified vehicles of the same sponsor, predating these roles and carrying none of them. The badge counts them; the figure beside this one does not.
Mergers closed across all 2 — these vehicles and the franchise's earlier ones together.
Announced but not closed, and still hunting — again over all 2.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Laurent D. Hermouet is a Partner and founding member of Athyrium Capital Management, a New York-based specialized asset management firm focused on investment opportunities in the global healthcare sector. In his role at Athyrium, Hermouet focuses on sourcing, diligencing, structuring, negotiating, and managing investments across the biotech, pharmaceutical, medtech, and pharma services industries. He is based out of New York, New York, and previously worked at Tribeca prior to co-founding Athyrium. The Athyrium investment team is led by Managing Partner Jeffrey A. Ferrell, alongside Partners Hermouet and Mark Kavulich, with a broader team of principals, associates, and operational professionals.
Hermouet has been involved in numerous notable healthcare financing transactions. In October 2018, he led Athyrium's $110 million credit facility to Kala Pharmaceuticals, supporting the commercialization of Inveltys (the first approved BID ocular corticosteroid for post-surgical inflammation and pain) and the development of KPI-121 0.25% for dry eye disease, with Morgan Stanley serving as sole structuring agent. He also participated in a significant balance sheet strengthening financing for Esperion Therapeutics, leveraging Athyrium's healthcare sector expertise. His broader investment portfolio and past investments span a wide range of healthcare companies, including BioCryst Pharmaceuticals, Secura Bio, Agendia, Sound Physicians, Veloxis, VillageMD, OptiNose, Recro Pharma, Progenity, Medicrea, Halozyme Therapeutics, Clover Health, Apollo Endosurgery, Travere Therapeutics, SynCardia Systems, InnoPharma, TRIA Beauty, and BioFire Diagnostics.
In the SPAC arena, Hermouet served as an independent director on the board of Blue Water Acquisition Corp. IV (NYSE: BWIV), a special purpose acquisition company led by CEO Joseph Hernandez. He filed a Form 3 with the SEC on March 23, 2026, disclosing his directorship, and was listed alongside fellow directors Trevor Leonard Hawkins and Timothy Neal Coulson. On May 9, 2026, Hermouet notified Blue Water Acquisition Corp. IV of his resignation from the board and all committee memberships, effective immediately; the company explicitly stated that his resignation did not arise from any disagreement with the company on any matter relating to its operations, policies, or practices, and indicated it was actively searching for a replacement. Prior to his service on Blue Water IV, Hermouet also served on the board of Blue Water Acquisition Corp. III, from which he resigned effective upon the closing of that company's business combination transactions, as disclosed in an 8-K filing received in late November 2025. His SPAC directorships reflect a pattern of involvement across the Blue Water Acquisition platform, where he contributed independent oversight during the pre-combination phase of each vehicle.
This record is keyed to SEC CIK 0002069721 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 4 institutional-holder rows on these vehicles, under 4 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.